ABB
5.6.2019 09:02:09 CEST | Business Wire | Press release
An independent study by marine consultancy Deltamarin revealed that the ABB Azipod® electric propulsion system for ferries could save up to $1.7 million in annual fuel costs per vessel, strengthening Azipod® propulsion’s market-leading position in sustainable marine technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005120/en/
By simulating a transit on seven existing ferry routes, researchers found that a ferry equipped with twin 10 MW mid-power range Azipod® units consumed less fuel compared to a similar vessel powered by a traditional shaftline propulsion system. Lower fuel consumption also means that the Azipod®-powered ferry would reduce CO2 emissions – by approximately 10,000 tons per year. This is equivalent to the amount of carbon dioxide emitted by about 2,200 passenger cars annually.
The global ferry industry, which transports 2.1 billion passengers every year, according to trade association Interferry, is facing increased pressure to meet the International Maritime Organization’s target of reducing annual emissions by 30 percent by 2025.
To help ferries improve energy efficiency and lower emissions, ABB is launching a new series of mid-power range Azipod® propulsion systems in June 2019. The latest Azipod® series will be available in the 7.5 to 14.5 MW power range and will fill the gap between the low and high-power range of Azipod® propulsors already in the market.
“We are continuously strengthening our portfolio of electric, digital and connected solutions that maximize the potential of ships and ultimately enable more sustainable operations,” said Peter Terwiesch, President of the Industrial Automation business at ABB, which offers solutions for a wide range of industries, including marine. “With the launch of the mid-power range Azipod® propulsion, we will be able to empower more shipowners to improve the performance of their vessels while lowering environmental impact.”
The Azipod® propulsion system, where the electric drive motor is in a submerged pod outside the ship hull, can rotate 360 degrees to increase maneuverability and operating efficiency, and has a proven ability to cut fuel consumption by up to 20 percent compared to traditional shaftline propulsion systems. Due to minimal noise and vibration, Azipod® propulsion also improves passenger and crew comfort. Azipod® propulsion systems have accumulated more than 15 million running hours, saving over 700,000 tons of fuel in the passenger cruise segment alone.
The latest Azipod® ‘M’ series is equipped with ABB’s fourth generation permanent magnet motors that draw on proven Azipod® propulsion technologies and have been refined to further increase power and maximize efficiency. The design simplicity of the system provides increased robustness and reliability, at the same time allowing for ease of maintenance.
With this expansion, the Azipod® propulsion family now covers the power range of 1-22 MW and is available for vessels from smaller crafts to icebreakers capable of independently operating in the harshest conditions. In addition to ferries and RoPax vessels that carry both vehicles and passengers, the mid-power range will also be applicable for larger offshore construction vessels, midsize cruise ships and shuttle tankers.
ABB – one of the world’s leading enablers of sustainable transportation – has already received several breakthrough orders in the ferry segment, including an Azipod® propulsion system for an LNG-powered Viking Line vessel due for delivery next year. Azipod® propulsion was also preferred by Finnish shipping company Wasaline for a recently ordered dual-fuel and battery power ferry, which will operate between Sweden and Finland.
“Building a future-proof, robust RoPax ferry requires proven technology that enables energy efficiency, saves valuable onboard space and provides increased passenger comfort. These features, coupled with superior maneuverability that would allow the ferry to operate a precise schedule crucial for a busy route, have made ABB’s Azipod® propulsion a natural choice for our newbuild project,” – said Peter Ståhlberg, CEO of Wasaline.
With over half of its global revenue generated from solutions that directly address the causes of climate change, ABB is at the forefront of sustainable development.
To watch the video, click here .
A summary of the Deltamarin study can be found here .
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005120/en/
Contact:
ABB Ltd Affolternstrasse 44 8050 Zurich Switzerland
Media Relations Phone: +41 43 317 71 11 Email: media.relations@ch.abb.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
